Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) had its target price upped by Mizuho from $7.00 to $10.00 in a research note issued to investors on Friday, Marketbeat.com reports. The firm presently has an “underperform” rating on the specialty pharmaceutical company’s stock. Mizuho’s price target suggests a potential downside of 52.83% from the company’s previous close.

Other analysts also recently issued reports about the company. Cantor Fitzgerald reissued a “buy” rating and set a $23.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, September 28th. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Monday, August 21st. ValuEngine raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. TD Securities raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Friday, November 3rd. Finally, Vetr downgraded Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $19.18 price objective for the company. in a research report on Monday, December 4th. Six investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $17.72.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded up $1.49 during trading hours on Friday, hitting $21.20. The company had a trading volume of 27,019,422 shares, compared to its average volume of 18,377,553. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. The firm has a market cap of $6,870.75, a P/E ratio of 3.20, a price-to-earnings-growth ratio of 0.54 and a beta of -0.22. Valeant Pharmaceuticals International has a 1 year low of $8.31 and a 1 year high of $22.81.

In other news, Director John Paulson bought 344,216 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was bought at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the transaction, the director now directly owns 94,559 shares in the company, valued at approximately $1,361,649.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.87% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Riggs Asset Managment Co. Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 118.2% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 4,512 shares during the period. Cetera Investment Advisers purchased a new position in shares of Valeant Pharmaceuticals International in the 2nd quarter valued at about $192,000. Harbour Capital Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals International in the 3rd quarter valued at about $224,000. American Century Companies Inc. purchased a new position in shares of Valeant Pharmaceuticals International in the 3rd quarter valued at about $238,000. Finally, Moors & Cabot Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 32.3% in the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock valued at $267,000 after buying an additional 3,725 shares during the period. 49.49% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/12/18/mizuho-trims-valeant-pharmaceuticals-international-vrx-target-price-to-7-00.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.